focus -WSS

focus

author：entertainment 2025-09-29 16:25:48 - browse：29258

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： What we know about the American soldier detained in North Korea

focus

WSS

Abbott's new stent may help patients with peripheral artery disease

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Cherokee Nation medical school graduates its first class

The United States must get value

Novo Nordisk testing Wegovy against alcohol

explore

focus

entertainment

Alkermes shareholders re

US soldier in North Korean custody after crossing DMZ line

Guidelines to prevent youth baseball injuries need more muscle

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Bright Health sells Medicare Advantage business to Molina

15 die by electrocution after transformer explodes in northern India

How one medical school became remarkably diverse

BridgeBio heart drug succeeds in pivotal study

Medical leaders decry Supreme Court decision on affirmative action

Study: Hearing aids may slow cognitive decline in those at risk

focus

As H5N1 spreads in cows, experts warn against drinking raw milk

WuXi Biologics execs register to lobby as Congress comes for the company

Cherokee Nation medical school graduates its first class

Manchin plays down potential 3rd

US soldier in North Korean custody after crossing DMZ line

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

explore

entertainment

focus

hotspot